期刊文献+

艾司西酞普兰治疗抑郁症患者的早期疗效及其与血药浓度的关系 被引量:7

Early efficacy and its correlation with plasma concentration of escitalopram in patients with depression
下载PDF
导出
摘要 目的:探讨艾司西酞普兰治疗抑郁症患者的早期疗效及其与血药浓度的关系。方法:对47例抑郁症患者应用艾司西酞普兰系统治疗,于治疗前及第1、2周进行汉密顿抑郁量表17项(HAND)评估,同时采用高效液相色谱-质谱法(HPLC-MS)测定血药浓度。结果:治疗1周有效率23.4%,无患者治愈;血药浓度在有效者[13.43±4.78)ng/ml]与无效者[(11.28±10.30)ng/ml]间差异无统计学意义。治疗2周治疗有效率59.6%,治愈率为25.5%;血药浓度有效者[(18.97±13.77)ng/ml]与治愈者[(19.65±11.42)ng/ml]差异无统计学意义,但均显著高于无效者[(6.52±3.36)ng/ml](P均<0.01)。有效者治疗1、2周时焦虑/躯体化因子分较无效者显著改善(P<0.05或P<0.01)。结论:艾司西酞普兰治疗抑郁发作(含伴焦虑)早期疗效良好;监测其血药浓度具有临床意义。 To explore the early efficacy and its correlation with plasma concentration of es-citalopram in patients with depression. Method:Forty-seven depressive patients receoived escitalopram sys-tem treatment. They were assessed by Hamilton rating scale for depression-17 items(HAMD)before treatment, one and two weeks after treatment. Meanwhile,their plasma concentration of escitalopram was detected by high performance liquid chromatography-mass spectrometry(HPLC-MS). Results:At the end of the first week,the effective rate was 23. 4± and no one was of cure. The plasma concentrations between the effective patient [(13. 43 ± 4. 78)ng/ ml]and invalid patients[(11. 28 ± 10. 30)ng/ ml]was no significantly difference. At the end of the second week,the effective rate was 59. 6± and cure rate was 25. 5± . The plasma concentrations be-tween the effective patient[(18. 97 ± 13. 77)ng/ ml]and the recovered patients[(19. 65 ± 11. 42)ng/ ml]was no significantly different;but all of those were significantly higher than invalid patients[(6. 52 ± 3. 36)ng/ml](all P ﹤ 0. 01). The scores of anxiety/ somatization factors of HAMD in effective patien at end of the first and second week were significantly improved than those in invalid patients(P ﹤ 0. 05 or P ﹤ 0. 01). Conclu-sion:The early efficacy of escitalopram in depressive patients(including combined anxiety)is good. Monitor the blood drug concentration has clinical significance.
出处 《临床精神医学杂志》 2014年第4期238-240,共3页 Journal of Clinical Psychiatry
关键词 艾司西酞普兰 抑郁症 血药浓度 depressive disorders escitalopram blood drug concentration
  • 相关文献

参考文献10

  • 1Hyttel J, Bogeso KP, Perregaard J, et al. The pharmacological effect of citalopram residues in the (S) - ( + ) -enantiomer [ J ]. J Neural Transm Gen Sect, 1992,88 : 157.
  • 2Lain RW,Andersen HF. The influenee of baseline severity on efficacy of escitalopram and citalopram in the treatment of major de- pressive disorder : an extended analysis [J]. Pharmaco Psychiatry, 2006,39 : 180.
  • 3Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants :a multiple-treat- ments meta-analysis[J]. Lancet,2009,373:746.
  • 4Thase ME. The Concept of Remission:validity and limitations [ J ]. C lin Psychiatry ,2006,67:478.
  • 5Wade A, Friis AH. The onset of effect for escitalopram and its rele- vance for the clinical management of depression [ J]. Curr Med Res Opin ,2006 ,22 : 2101.
  • 6Sanchez C, Braestrup C. Escitalopram : a unique mechanism of action [ J ]. J Psych Clin Pract,2004,8 (Suppl) : S11.
  • 7Chen F, Larsen MB, Sanchez C, et al. The S-enantiomer of R, S- citalopram, increases inhibitor binding to the human serotonin transporter by anallosteric mechanism. Comparison with other sero- tonin transporter inhibitors [J]. Eur Neuropsychopharmacol, 2005, 15 : 193.
  • 8Olie JP,Tonnoir B,Menard F. A prospective study of escitalopram in the treatment of major depresssive episodes in the presence or absence of anxiety [ J ]. Depress Anxiety,2007,24 : 318.
  • 9Lam RW, Annemans L. Efficacy, effectiveness and efficiency of es- citalopram in the treatment of major depressive and anxiety disor- ders[ J]. Expert Rev Pharmacoecon Outcomes Res,2007 ,7 :559.
  • 10Dhillon S, Scott LJ, Plosker GL. Escitalopram : a review of its use in the management of anxiety disorders [ J ]. CNS Drugs, 2006, 20:763.

同被引文献65

  • 1黄素培,蒋立新,王来海.抗抑郁药物的作用特点与临床应用[J].临床心身疾病杂志,2004,10(4):298-300. 被引量:6
  • 2汪春运,臧家平.氟西汀的临床应用[J].医药导报,2005,24(10):897-899. 被引量:4
  • 3司天梅,舒良.关于新抗抑郁药艾司西酞普兰[J].临床精神医学杂志,2007,17(1):68-69. 被引量:124
  • 4WorldHealthOrganization,WorldOrganizationofFamilyDoctors.Integratingmentalhealthintoprimarycare:aglobalperspective[M].Geneva:WorldHealthOrganization,2008:23.
  • 5WorldHealthOrganization.Theglobalburdenofdisease:2004update[M].Geneva:WorldHealthOrganization,2008.
  • 6KraaijV,ArensmanE,SpinhovenP.Negativelifeeventsandde-pressioninelderlypersons:ametaanalysis[J].JGerontolBPsy-cholSciSocSci,2002,57(1):87-94.
  • 7郑莜萸.中药新药临床研究指导原则(试行)[s].中国医药科技出版社,2002:352—353.
  • 8Karg K, Burmeister M, Shedden K, et al. The serotonin transport- er promoter variant ( 5 - HTYLPR ), stress, and depression meta - analysis revisited : evidence of genetic moderation [ J ] Ar- chives of general psychiatry, 2011,68 ( 5 ) : 444 - 454.
  • 9陈彦方.中国精神疾病分类方案与诊断标准(CCND-III)[s].3版.济南:山东科学技术出版社,2001:243.
  • 10鲁杰,熊世熙.艾司西酞普兰对血糖及血脂的影响[J].中国民康医学,2010,22(17):2242-2242. 被引量:7

引证文献7

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部